Apogee Therapeutics Inc (APGE)

Currency in USD
62.13
-2.75(-4.24%)
Closed·
62.72+0.59(+0.95%)
·
APGE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
62.0167.62
52 wk Range
26.2084.56
Key Statistics
Prev. Close
62.13
Open
64.78
Day's Range
62.01-67.62
52 wk Range
26.2-84.56
Volume
709.02K
Average Volume (3m)
949.24K
1-Year Change
49.2075%
Book Value / Share
10.01
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
APGE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
104.29
Upside
+67.85%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Apogee Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Apogee Therapeutics Inc Company Profile

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Compare APGE to Peers and Sector

Metrics to compare
APGE
Peers
Sector
Relationship
P/E Ratio
−16.5x−2.0x−0.5x
PEG Ratio
0.300.200.00
Price/Book
7.2x6.3x2.6x
Price / LTM Sales
-8.1x3.3x
Upside (Analyst Target)
49.3%44.3%48.1%
Fair Value Upside
Unlock3.6%7.7%Unlock

Analyst Ratings

14 Buy
2 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 104.29
(+67.85% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jefferies
Buy95.00+52.91%98.00MaintainFeb 02, 2026
RBC Capital
Hold83.00+33.59%70.00DowngradeJan 22, 2026
Craig-Hallum
Buy116.00+86.71%109.00MaintainJan 07, 2026
UBS
Buy100.00+60.95%-New CoverageJan 07, 2026
Wolfe Research
Hold---New CoverageJan 07, 2026

Earnings

Latest Release
Nov 10, 2025
EPS / Forecast
-1.11 / -0.61
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

APGE Income Statement

People Also Watch

11.880
ERAS
+5.69%
53.91
PCVX
-2.48%
110.71
ABVX
-2.52%
29.46
TYRA
-4.26%
7.27
KYTX
-4.59%

FAQ

What Is the Apogee Therapeutics (APGE) Stock Price Today?

The Apogee Therapeutics stock price today is 62.13

What Stock Exchange Does Apogee Therapeutics Trade On?

Apogee Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Apogee Therapeutics?

The stock symbol for Apogee Therapeutics is "APGE."

What Is the Apogee Therapeutics Market Cap?

As of today, Apogee Therapeutics market cap is 4.19B.

What Is Apogee Therapeutics's Earnings Per Share (TTM)?

The Apogee Therapeutics EPS (TTM) is -4.36.

When Is the Next Apogee Therapeutics Earnings Date?

Apogee Therapeutics will release its next earnings report on Mar 10, 2026.

From a Technical Analysis Perspective, Is APGE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Apogee Therapeutics Stock Split?

Apogee Therapeutics has split 0 times.

How Many Employees Does Apogee Therapeutics Have?

Apogee Therapeutics has 196 employees.

What is the current trading status of Apogee Therapeutics (APGE)?

As of Feb 06, 2026, Apogee Therapeutics (APGE) is trading at a price of 62.13, with a previous close of 62.13. The stock has fluctuated within a day range of 62.01 to 67.62, while its 52-week range spans from 26.20 to 84.56.

What Is Apogee Therapeutics (APGE) Price Target According to Analysts?

The average 12-month price target for Apogee Therapeutics is USD104.29, with a high estimate of USD137 and a low estimate of USD83. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +67.85% Upside potential.

What Is the APGE After Hours Price?

APGE's last after hours stock price is 62.72, the stock has decreased by 0.59, or 0.95%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.